DOCSLIB.ORG

Consultation on Potential Ebola Therapies and Vaccines 4-5 September 2014 Geneva, Starling Hotel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Consultation on Potential Ebola Therapies and Vaccines 4-5 September 2014 Geneva, Starling Hotel Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel List of participants: 1. Dr Marylyn Addo, Professor of Emerging Infections, Universitätsklinikum Hamburg‐Eppendorf, German Center of Infectious Diseases Research (DZIF), Hamburg, Germany 2. Dr Clement Adebamowo, Chairman, National Health Research Ethics Committee of Nigeria, Federal Ministry of Health, Abuja, Nigeria 3. Dr Selidji Agnandji, Franceville, Gabon 4. Dr Enrica Alteri, Head of Safety and Efficacy of Medicines, Human Medicines Development and Evaluation Unit, European Medicines Agency, London, United Kingdom of Great Britain & Northern Ireland 5. Dr Sylvain Baize, Biology of Viral Emerging Infections, Institut Pasteur, Paris, France 6. Dr Younoussa Ballo, Secrétaire general, Ministère de la Santé, Conakry, Guinea 7. Dr Ripley Ballou, GlaxoSmithKline Biologicals SA, Rixensart, Belgium 8. Ms Helia Baradarani, Tekmira’s Manager of Medical Countermeasure Business Development, Vancouver, Canada 9. Dr Jarbas Barbosa, Vice Minister, Ministry of Health, Brasilia, Brazil 10. Dr Jesus Barral‐Guerin, Senior Manager, Vaccine Centre, Supply Division, UNICEF, Copenhagen, Denmark 11. Dr Daniel Bausch, Associate Professor, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans, USA 12. Dr Sina Bavari, CIV US Army Medcom USA MRIID, USA 13. Dr Stephan Becker, Direktor, Institut für Virologie, Marburg, Germany 14. Dr Laetitia Bigger, Senior Manager, Vaccines Policy, IFPMA, Geneva, Switzerland 15. Dr Fred Binka, Vice Chanceller, University of Health and Allied Sciences, Ho, Ghana 16. Dr Francisco Blanco, Chief of Medicines & Nutrition, Supply Division, UNICEF, Copenhagen, Denmark 17. Dr Luciana Borio, Director, Office of Counterterrorism and Emerging Threats (OCET) in the Office of the Chief Scientist, U.S. Food and Drug Administration (FDA), Rockville, USA Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 18. Dr Abdullah Brooks, Centre for Health and Population Research, Dhaka, Bangladesh 19. Dr Philippe Calain, Unité de Recherche sur les Enjeux et Pratiques humanitaires (UREPH), Médecins sans Frontières, Geneva, Switzerland 20. Dr Michael Callahan, Command Physician, Rescue Medicine/Réseau Médical Patient Filovirus, Kinsasha, Harvard Medical School, Massachusetts General Hospital, Boston, USA 21. Dr Benoit Callendret, Crucell, Leiden, Netherlands 22. Dr Iris Chang, Hong Kong Academy of Pharmacy, Hong Kong, People’s Republic of China 23. Dr George Christopher, Chief Medical Officer, Joint Project Manager – Medical Countermeasure Systems, Department of Defense, Rockville, USA 24. Dr Supamit Chunsuttiwat, Senior Medical Officer, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand 25. Dr Jacob Cohn, Bavarian Nordic A/S, Kvistgaard, Denmark 26. Dr Christoph Conrad, Paul‐Ehrlich‐Institut, Langen, Germany 27. Mr Stephan Cook, Vice President, Vaccine Global Regulatory Affairs, Vaccine Value & Health Science, GlaxoSmithKline Biologicals SA, Rixensart, Belgium 28. Dr Marion Danis, Head, Section on Ethics and Health Policy, NIH, Bethesda, USA 29. Prof Jean‐François Delfraissy, Director of Agence nationale de Recherche (ANRS), Paris, France 30. Dr Martin de Smet, Médecins sans Frontières, Brussels, Belgium 31. Dr Antal Tal Dia, Chairman, National Immunization Technical Advisory Group (NITAG) Senegal, Dakar, Senegal 32. Dr Alpha Amadou Diallo, Rapporteur du Comité national d’Ethique et de Recherche en Santé, Conakry, Guinea 33. Prof Ousmane Doumbia, Secrétaire general, Ministère de la Santé et del'Hygiène publique, Bamako, Mali 34. Dr Karifa Douno, Chef, Division Etablissements biopharmaceutiques, Ministère de la Santé, Conakry, Guinea 35. Dr Mattias Egger, Professor of Epidemiology and Public Health, University of Bern, Bern, Switzerland 2 Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 36. Dr Lindsay Elmgren, Director, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada 37. Dr Carol Epstein, MediVector, Inc. Fujifilm Pharmaceuticals USA, Boston, USA 38. Dr Jeremy Farrar, Director, Wellcome Trust, London, United Kingdom of Great Britain & Northern Ireland 39. Dr Patricia Fast, International AIDS Vaccine Initiative, New York, USA 40. Dr Eleanor Fish, University of Toronto, Toronto, Canada 41. Prof Fu Gao, Deputy Director General for sciences, China CDC, Beijing, China 42. Dr Jennifer Gibson, Director, Joint Centre for Bioethics, Director, World Health Organization Collaborating Centre for Bioethics, Associate Professor, Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Canada 43. Dr Dennis Giesing, Vice President, Preclinical Research, MediVector, Inc. Fujifilm Pharmaceuticals USA, Boston, USA 44. Dr Jesse Goodman, George Town University, Washington, USA 45. Dr Barney Graham, Vaccine Research Centre, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA 46. Dr Nyankoye Haba, National Blood Service, Conakry, Guinea 47. Dr Fred Hayden, University of Virginia/WHO consultant, Charlottesville, USA 48. Dr Lisa Hensley, National Institute of Allergy and Infectious Diseases, NIH , Bethesda, USA 49. Dr Elizabeth Higgs, Global Health Science Advisor, Office of the Director, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA 50. Dr David Hone, Chief, Vaccine Branch, Research and Development Directorate (J9), Defense Threat Reduction Agency (DTRA), Department of Defense, Fort Belvoir, USA 51. Dr Peter Horby, University of Oxford, Oxford, United Kingdom of Great Britain & Northern Ireland 52. Dr Angela Huttner, Infection Control Programme, University Hospitals of Geneva, Switzerland 53. Dr Ryuichi Ida, Member of the Expert Panel on Bioethics (National Bioethics Committee), Kyoto, Japan 3 Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 54. Dr Giuseppe Ippolito, Scientific Director, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy 55. Dr Ambrose Isah, GACVS representative, Benin City, Nigeria 56. Dr Aikichi Iwamoto, The Institute of Medical Sciences, Research Center for Asian Infectious Diseases, Japan 57. Dr Amandua Jacinto, Commissioner Clinical Services, Ministry of Health and Social Welfare, Kampala, Uganda 58. Mrs Markieu Janneh‐Kaira, Chief Pharmacist/ Registrar, National Pharmaceutical Services, Ministry of Health & Social Welfare, Banjul, The Gambia 59. Dr Franca Jones, Medical Director, Chemical and Biological Defense Program, Office of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs OASD(NCB/CB), Rockville, USA 60. Mrs Markieu Janneh‐Kaira, Chief Pharmacist/ Registrar, National Pharmaceutical Services, Ministry of Health and Social Welfare, Banjul, The Gambia 61. Ms Sadia Kaenzig, Manager, Communications, IFPMA, Geneva Switzerland 62. Dr Robinah Kaitiritimba, Uganda National Health Consumers' Organisation (UNHCO), Kampala Uganda 63. Dr Samuel Kargbo, Director, Reproductive and Child Health, Ministry of Health and Sanitation, Freetown, Sierra Leone 64. Dr Christopher Karp, Deputy Director, Discovery and Translational Sciences, Bill & Melinda Gates Foundation, Seattle, USA 65. Dr Francis N. Kateh, Medical Director / CEO, Jackson F. Doe Memorial Regional Referral Hospital, Tappita City, Lower Nimba County, Liberia 66. Dr Steve Kern, Deputy Director, Integrated Development, Bill & Melinda Gates Foundation, Seattle, USA 67. Dr Nadia Khelef, Institut Pasteur, Paris, France 68. Dr Hiroshi Kitaguchi, General Manager, Business Development Department, Toyama Chemical Co., Ltd., Tokyo, Japan 69. Dr Gary Kobinger, Public Health Agency of Canada, Vancouver, Canada 70. Dr Daniel Koch, Federal Office of Public Health, Bern, Switzerland 4 Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 71. Dr Mandy Kader Kondé, Président de la Commission Recherche Ebola, Conakry, Guinea 72. Dr Bocar Kouyate, Office of the Minister of Health, Ouagadougou, Burkina Faso 73. Dr Sanjeev Krishna, London, United Kingdom of Great Britain & Northern Ireland 74. Dr Michael Kurilla, Director, Office of BioDefense, Research Resources, and Translational Research, Associate Director for BioDefense Product Development, NIAID, NIH, Rockville, USA 75. Dr Randall Lanier, Executive Director of Biology, Chimerix Inc., Durham, USA 76. Dr James Lawler, Director, ACESO/Clinical Research Partner in Uganda, Kampala, Uganda 77. Dr Robert Lenk, EVP and CSO, MediVector, Boston, USA 78. Dr Bertand Lepine, FabEntech, Lyon, France 79. Dr Mike Levine, Director, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA 80. Dr Nicole Lurie, Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services, Washington, USA 81. Dr Ian MacLachlan, Executive Vice President and Chief Technical Officer, Tekmira Pharmaceuticals Corp., Vancouver, Canada 82. Dr Alan Magill, Director, Malaria, Bill & Melinda Gates Foundation, Seattle, USA 83. Prof Denis Malvy, Professor in Infectious Diseases, Bordeaux, France 84. Dr Brian K. Martin, Director, Infectious Disease Division, BioProtection Systems, a wholly‐owned subsidiary of NewLink Genetics, Ames, USA 85. Dr Jacques‐François Martin, Fab Entech, Lyon,
Load more

Recommended publications
  • Cytokines MONTRÉAL 2008
    Cytokines MONTRÉAL 2008 Translating Science into Health: Cytokines in Cancer, Infl ammation and Infectious Diseases 7th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research Photo: Tourisme Montréal Photo: Tourisme October 12-16, 2008 Fairmont Queen Elizabeth Hotel Montreal Quebec CANADA Cytokines Montreal 2008 1 PROGRAM From cell separation to molecular analysis The Gold Standard in Cell Isolation • Separation of functional, cytokine-secreting cells • Virtually any cell type from any species • Superior viability, purity and recovery Cytokines and Growth Factors • New, broad portfolio: human - mouse - rat • Excellent purity and activity • Optimized for cell culture applications MACSmolecular Tools for Molecular Analysis • Tools for signal transduction • State of the art microRNA analysis • Comprehensive gene expression profiling Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. Miltenyi Biotec Inc. Phone 800 FOR MACS www.miltenyibiotec.com 12740 Earhart Avenue +1 530 888 8871 [email protected] Auburn CA 95602, USA Fax +1 530 888 8925 2 Cytokines Montreal 2008 ContentsWelcome to Montreal ..................................................................................... 4-5 Sponsors and Exhibitors ................................................................................... 6 Conference Venue ...........................................................................................
    [Show full text]
  • Beyond Vaccines: Promising Therapeutics for COVID-19 and Emerging Viruses
    Research Canada speaks to Dr. Eleanor Fish, a scientific advisor to Canada’s COVID- 19 Therapeutics Task Force Beyond Vaccines: Promising Therapeutics for COVID-19 and Emerging Viruses The federal government’s COVID-19 Therapeutics Task Force provides advice on the best and most promising treatments for COVID-19 procurement, whether these are still in development and merit support, including via applications to the federal Strategic Innovation Fund, or are existing medications. The Task Force also makes recommendations on therapies developed for a different use that may have an application to COVID-19. Dr. Eleanor Fish is among 11 science advisors to the Therapeutics Task Force. A Professor of Immunology at the University of Toronto and a Senior Scientist at University Health Network, she investigates the behaviour of cytokines, which play a role in cell-to-cell communication during the body’s immune response. In a recent Research Canada interview with Ms. Deborah Gordon-El- Bihbety, President and CEO, Dr. Fish talked about the critical place of therapeutics in the battle against COVID-19, and their important role in preparing for the diseases and epidemics to come. "Vaccines are a very important tool in our toolbox against COVID-19, but they are not a complete solution." - Dr. Eleanor Fish 1 RESEARCH CANADA: Canada’s vaccination campaign is under way, and we’ve been told that all Canadians who want a vaccine will have it by next fall. What role do therapeutics play, separate from vaccines, in the fight against COVID-19? DR. ELEANOR FISH: Vaccines are a very important tool in our toolbox against COVID-19, but they are not a complete solution.
    [Show full text]
  • ISICR Vol. 15.1
    ISICR Officers President Eleanor Fish President-elect INTERNATIONAL SOCIETY FOR Leonidas Platanias INTERFERON AND CYTOKINE RESEARCH Secretary April 2008 Tom Hamilton Volume 15, No. 1 Treasurer Bob Friedman Executive Director A Message from the new ISICR Cliff Brownstein President, Eleanor Fish It is with gratitude and humility that I assume the Future ISICR Meetings responsibilities of incoming President of the ISICR. I am honored to have been elected by my peers and am fortunate to have in place a Board of 2008 Meeting Directors and Committee members that are as Joint ISICR/ICS committed to strengthening our Society as I am. In Montreal, Canada recent months, to ensure that our Society reflects Oct. 12-16 the scientific activities of junior investigators, as positions have www.cytokines2008.org become vacant on the various ISICR Committees, in consultation 2009 Meeting with the Committee Chairs I have made best efforts to invite the par- Joint ISICR/ICS/SLB ticipation of younger investigators who share our vision of a strong, Lisbon, Portugal international, collegial Society. I invite members to participate in your Society - just contact me to let me know of your interest. 2010 Meeting Joint ISICR/ICS Within recent years we have seen a revival of interest in the Chicago, Illinois pleiotropic activities of interferons, touching on many different bio- logical disciplines. Moreover, the role of cytokines and how they ISICR WWW Site inform us of biological processes in normal and diseased states is an www.ISICR.org ever expanding field. I would like to focus my tenure as President on a number of key areas: ISICR Business Office O Communication.
    [Show full text]
  • Dec 08 News Vol 15 No 3 Final.Qxp
    ISICR Officers President Eleanor Fish President-elect Leonidas Platanias Secretary Tom Hamilton December 2008 - Volume 15, No. 3 Treasurer Bob Friedman Executive Director One on one: An Interview with Cliff Brownstein Giorgio Trinchieri, Recipient of the 2008 Milstein Award Future ISICR Meetings Thomas Tan 2009 Meeting Giorgio Trinchieri received his medical degree Joint ISICR/ICS/SLB from the University of Torino, Italy, in 1973. He Lisbon, Portugal was a member of the Basel Institute for Immunology (Basel, Switzerland) and an investi- 2010 Meeting gator at the Swiss Institute for Experimental Joint ISICR/ICS Cancer Research (Epalanges sur Lausanne, Chicago, Illinois Switzerland). From 1979 to 1999 he was at Wistar Institute in Philadelphia and became Hilary Koprowski Professor and Chairman of the Immunology Program; he ISICR WWW Site was also Wistar Professor of Medicine at the University of www.ISICR.org Pennsylvania. He then served as director of the Schering Plough Laboratory for Immunological Research in Dardilly, France, and an ISICR Business Office NIH Fogarty Scholar at the Laboratory for Parasitic Diseases, [email protected] NIAID, before becoming director of the Cancer and Inflammation TEL: 301-634-7250 Program (CIP) and Chief of the Laboratory of Experimental FAX: 301-634-7420 Immunology at NCI in August 2006. As CIP director, he oversees the operations of two major NCI intramural laboratories, the Laboratory ISICR Newsletter Editors of Experimental Immunology and the Laboratory of Molecular Howard Young Immunoregulation. These two laboratories constitute the major [email protected] immunologic component of the inflammation and cancer initiative, Fax: 301-846-1673 which spans the NCI's campuses in Frederick and Bethesda and seeks Hannah Nguyen to partner NCI's expertise in inflammation and immunology with its cutting-edge cancer etiology and carcinogenesis program.
    [Show full text]
  • Official Transcript
    Under the Microscope Expert Webinar on COVID-19 Vaccine Research in Australia & Germany Official Transcript On 30 June 2020, the Australian Embassy Berlin hosted an expert webinar to discuss the race for a COVID-19 vaccine. The event was was supported by the German Embassy Canberra, the Australian Academy of Science, and the Australia- Germany Research Network (AGRN). Ambassador H.E. Laureate Professor Professor Doctor Emeritus Professor Paul Richards Lynette Wood Peter Doherty Marylyn Addo Hans Bachor This live webinar took place on 30 June 2020, when the world had just crossed over 10 million infections and 500,000 deaths due to COVID-19. The date was on the eve of the six month mark since WHO received the first reports of a cluster of cases of pneumonia of unknown cause in China. Due to technical issues with the recording, we are not able to provide a high-quality audio or video recording of the webinar. Instead, we provide below a transcript of the webinar. We hope you find it useful and informative. 2 Panellists Laureate Professor Peter Doherty is one of Australia’s leading immunologists. Professor Doherty is the patron of the eponymous Doherty Institute, which has been at the forefront of Australia’s response to the COVID-19 pandemic. The Institute is currently investigating two protein-based and two viral vector vaccines. Professor Doherty and Swiss researcher Rolf Zinkernagel were awarded the Nobel Prize in Physiology or Medicine in 1996 for their discoveries of how the immune system recognises virus-infected cells, a discovery which has had practical implications for cancer treatments.
    [Show full text]
  • CMAJ WHO Enters New Terrain in Ebola Research
    CMAJ News WHO enters new terrain in Ebola research he meeting on unproven inter- ventions for Ebola at the World T Health Organization on Sept. 4 and 5 takes the global agency into “absolutely uncharted territory,” says WHO spokesperson, Dr. Margaret Harris. “We’re actually often criticized for being incredibly slow about saying, ‘Do this over that’, because we demand enormous levels of evidence,” she says. But for Ebola virus disease, there are no approved therapies, so WHO is attempting to move investigational interventions forward, including medi- cations, vaccines and so-called conva- lescent serum, made from the blood of survivors. The Sept. 4 meeting, aimed at guid- ing research in the midst of the out- NikiLitov/iStock/Thinkstock break, marks a sharp turn for WHO, In the absence of approved therapies for patients diagnosed with Ebola, WHO is taking where research efforts are viewed as the unprecedented step of attempting to move research forward. fragmented. About five years ago, WHO eliminated its office of research break at 78%, and in late August the three control animals died. Five of the strategy; the department leading the disease spread to another country — seven people treated with ZMapp have Ebola research effort, known as Senegal — and another city — Port survived, but it is unclear if the medica- Knowledge, Ethics and Research, was Harcourt, Nigeria, the hub of Nigeria’s tion helped them to recover and it will only formed at the end of 2013. But the oil and gas industry, where Canadian be months before there is more ZMapp Ebola crisis forced a change.
    [Show full text]
  • Keynote Speakers
    Keynote Speakers Dr. Katie Flanagan, BA(Hons) MBBS DTM&H MA PhD CCST FRCP FRACP, leads the Infectious Diseases Service at Launceston General Hospital in Tasmania, and is a clinical Associate Professor at the University of Tasmania, Australia. She obtained a degree in Physiological Sciences from Oxford University, followed by her MBBS from the University of London. She is a UK and Australia accredited Infectious Diseases Physician. Katie obtained her PhD in malaria immunology based at Oxford University. She was previously Head of Infant Immunology Research at the MRC Laboratories in The Gambia from 2005-11. Dr. Thumbi Ndung’u, BVM, PhD, is the Scientific Director of the HIV Pathogenesis Programme at the University of KwaZulu Natal in South Africa. He is a virologist with a PhD from Harvard University, Boston, USA. His main research interests are in host-virus interactions and immune responses in HIV-1 infection. He is also interested in the development of biomedical interventions that can be used in resource-limited settings to prevent or treat HIV/AIDS. He is an Associate Professor in HIV/AIDS Research at the the Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal. He holds the South African Department of Science and Technology/National Research Foundation (DST/NRF) Research Chair in Systems Biology of HIV/AIDS. Dr. Josef Penninger BA, MD, PhD, is Scientific Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. He is Professor in the Departments of Immunology and Medical Biophysics at the University of Toronto, Canada, Professor of Genetics, University of Vienna, Austria, Honorary Professor of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing, China, Affiliate Scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute of St.
    [Show full text]
  • The Dynamic Changes in Cytokine Responses in COVID-19
    meeting report SARS-COV-2 The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge “The role of cytokines in COVID-19” online symposium was presented on 18 June 2020 by the NIH/FDA Immunology and Cytokine Interest Groups and was purposed to discuss our rapidly changing understanding of COVID-19-related cytokine responses in diferent stages of infection, including the etiologies, downstream consequences and possible mitigation strategies. The recording is available at https://nci.rev.vbrick.com/ sharevideo/03106730-66cc-47ba-870b-f6e6274a998a. he symposium was opened by address that underscored the broad variety serum cytokine concentrations with disease Anthony Fauci, Director of the of clinical presentations of COVID-19, outcome. Her data showed that IL-6, IL-8 TNational Institute of Allergy and thus highlighting the central role of the and TNF, and to a lesser extent, IL-1β, were Infectious Diseases at the US National immune response in this disease. She also elevated at the time of hospitalization, and Institutes of Health (NIAID, NIH), and remarked on the apparent geographic their concentrations correlated with disease Janet Woodcock, Director of the Center clusters of disease manifestations and the outcome and mortality, even after correcting of Drug Evaluation and Research, Food need to better understand possible factors for age, ethnicity, race and comorbidities, and Drug Administration (CDER, FDA) in host–pathogen interactions beyond those suggesting that they could be used to and currently leading the therapeutics health conditions already identified, such identify patients at risk of severe disease2. component of Operation Warp Speed.
    [Show full text]
  • December 2012
    Department of Immunology Newsletter image provided by Michael Corrin VOL I – ISSUE 4 December 2012 Message from the Chair, UPCOMING SEMINARS Dr. Juan Carlos Zúñiga-Pflücker EASTON SEMINARS – Another year, another spectacular Immunology Holiday Party for January 2013 which we have Alessandra Ferzoco, Elisa Porfilio and many IGSA Room 2172 MSB at 11:10 a.m. members to thank. Jennifer Gommerman’s Mayan inspired January 14, 2013 apocalyptic monologue was terrific, and terrifying if we really had Richard M. Ransohoff, MD to choose whom to save. For those that could not make it, I am “Monocytes and microglia: Where they sorry, you missed a wonderful evening, but here is a recap of some come from and what they do.” (Host: Dr. Eleanor Fish) key items: the Richard Miller award was given to Janet Markle (Danska lab) and the Bernhard Cinader award by was given to January 21, 2013 Peter Chen (Carlyle lab); the Examiner of the Year award went to Jorge Kalil, MD, PhD “From molecular immunopathogenesis Michele Anderson, with Alberto Martin as a close runner-up. Our to the development of a vaccine to avoid department’s long-running holiday party DJ, Ernie West, was a post infectious human autoimmune recognized for his many years of service, and James Carlyle won disease.” (Host: Dr. Michelle Letarte) the newly minted “Lord of the dance” gold record award. The centerpiece competition winners were from the Kelly MacDonald January 28, 2013 lab, and the Zúñiga-Pflücker lab as runner-ups. The new fashion- Jeremy Mogridge, PhD show competition award was won by Catherine Schrankel (Rast “Detection of danger by the Nlrp1b inflammasome.” lab).
    [Show full text]
  • German Center for Infection Research
    GERMAN CENTER FOR INFECTION RESEARCH Annual Report 2018 Cover image: This image shows a scanning electron microscope image of thread-like Ebola viruses (in blue) protruding from an infected cell. ANNUAL REPORT 2018 The DZIF at a glance The German Center for Infection Research (DZIF) coordinates and oversees the strategic planning of translational infection research within Germany. Its mission is to translate results from basic biomedical research into clinical research. 35 DZIF research centres work concertedly against the global threat of infectious diseases. Table of contents Editorial ............................................................................................................................................................................. 3 About the DZIF ............................................................................................................................................................. 4 Science – Translation in focus Emerging Infections ................................................................................................................................................. 6 Tuberculosis ................................................................................................................................................................... 8 Malaria .............................................................................................................................................................................. 10 HIV .......................................................................................................................................................................................
    [Show full text]
  • Murine Hepatitis Virus Strain 1 As a Model for Severe Acute Respiratory Distress Syndrome (Sars)
    MURINE HEPATITIS VIRUS STRAIN 1 AS A MODEL FOR SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (SARS) Nadine DeAlbuquerque, Ehtesham Baig, Max Xuezhong, Itay Shalev, M. James Phillips, Marlena Habal, Julian Leibowitz, Ian McGilvray, Jagdish Butany, Eleanor Fish, and Gary Levy* 1. INTRODUCTION Severe acute respiratory syndrome (SARS) is a novel infectious disorder that was first diagnosed in China in November 2002.1,2 SARS was documented in approximately 8,000 persons globally with more than 700 deaths. In Canada, there were 375 probable and suspect cases between March and July 2003 with 44 deaths, reflecting a mortality rate of 11%. Spread of SARS was shown to be by airborne droplets and results in acute pulmonary inflammation and epithelial damage.3 It has now been determined that a novel coronavirus, SARS-CoV, is the etiologic agent in SARS. Based on phylogenetic sequence analysis, it best fits within group 2 coronaviruses, which include the mouse hepatitis viruses (MHV).4,5 As for most infections, SARS varies considerably in terms of its clinical severity. This variation is almost certainly due to population-based diversity in the genes controlling the immune response. Clearance of mouse hepatitis virus coincides with a robust innate immune response, including increased numbers of CD8 T cells. Disease and death do not correlate with high viral titers, and it has been suggested that disease reflects alteration in host innate immune response. Furthermore, host production and response to type 1 interferons (IFN) is a key determinant of outcome in MHV-infected mice.6 However, IFNs and other cytokines regulate in a coordinate manner both inflammation and the Th1/Th2 character of the specific immune response.
    [Show full text]
  • Therapeutic Effectiveness of Interferon-Alpha 2B Against COVID-19: the Cuban Experience
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.29.20109199; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience Pereda R1, González D1, Rivero HB1, Rivero JC1, Pérez A1, López LR1, Mezquia N1, Venegas R1, Betancourt JR2, Domínguez RE3. 1 Medical college of Havana. Havana city, Cuba. 2 Medical college of Villa Clara. Santa Clara city, Cuba. 3 Medical college of Camaguey. Camagüey city, Cuba. Correspondence to: Ricardo Pereda González Cuban Ministry of Public Health 202, 23 Street, Vedado, Plaza de la Revolución. Havana, Cuba [email protected] key words: interferon, COVID-19, SARS-Cov-2 NOTE: This preprint reports new research that has not been certified1 by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.05.29.20109199; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. ABSTRACT Background Effective therapies are needed to control the SARS-Cov-2 infection pandemic and reduce mortality associated with COVID-19. Several clinical studies have provided evidence for the antiviral effects of type I interferons (IFNs) in patients with respiratory coronaviruses.
    [Show full text]